Germline mutation of the CCK receptor: A novel biomarker for pancreas cancer

Jelal Alsubai, Gail Matters, Christopher O. Mcgovern, Jiangang (Jason) Liao, Evan L. Gilius, Jill P. Smith

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives:Today, genetic biomarkers have been demonstrated to play an important role in identifying at-risk subjects for familial or inherited cancers. We have identified a single-nucleotide polymorphism (SNP) that results in missplicing of the cholecystokinin (CCK) receptor gene and expressing a larger mutated receptor in pancreatic cancer. The purpose of this study was to evaluate the significance and specificity of this SNP as a potential biomarker in patients with pancreatic cancer compared with other gastrointestinal (GI) cancers that also have CCK receptors.Methods:DNA was isolated and genotyped for the CCK receptor SNP from frozen tumor tissue from banked specimens of patients with pancreas, gastric, or colon cancer and from human cancer cell lines. Genotype and allelic frequencies were compared between the cancer cohort and two normal control databases using Fisher's exact test and odds ratio (OR). The Kaplan-Meier method was used to estimate the survival for patients with the CCK-B receptor SNP compared with those with the wild-type genotype. Immunohistochemical staining of cancer cells was done to detect the mutated receptor.Results:Colon and gastric cancer patients had similar genotype frequencies for the CCK receptor SNP as that reported in the normal population. In contrast, the prevalence of the SNP in subjects with pancreatic cancer was twice that of controls and other GI cancers. Survival was adversely affected by the presence of the SNP only in those with pancreatic cancer. Immunoreactivity for the mutated receptor was positive in pancreatic cancer tissues with the SNP but absent in other GI cancers.Conclusions:A SNP of the CCK receptor is significantly increased in patients with pancreatic cancer but not in those with other GI malignancies. Therefore, this SNP may be a potential biomarker for pancreatic cancer.

Original languageEnglish (US)
Article numbere134
JournalClinical and Translational Gastroenterology
Volume7
DOIs
StatePublished - Jan 7 2016

Fingerprint

Cholecystokinin A Receptor
Germ-Line Mutation
Pancreatic Neoplasms
Single Nucleotide Polymorphism
Biomarkers
Cholecystokinin Receptors
Gastrointestinal Neoplasms
Neoplasms
Genotype
Colonic Neoplasms
Stomach Neoplasms
Cholecystokinin B Receptor
Survival
Odds Ratio

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

@article{51547450cbf94db49135bdc1a1453a0c,
title = "Germline mutation of the CCK receptor: A novel biomarker for pancreas cancer",
abstract = "Objectives:Today, genetic biomarkers have been demonstrated to play an important role in identifying at-risk subjects for familial or inherited cancers. We have identified a single-nucleotide polymorphism (SNP) that results in missplicing of the cholecystokinin (CCK) receptor gene and expressing a larger mutated receptor in pancreatic cancer. The purpose of this study was to evaluate the significance and specificity of this SNP as a potential biomarker in patients with pancreatic cancer compared with other gastrointestinal (GI) cancers that also have CCK receptors.Methods:DNA was isolated and genotyped for the CCK receptor SNP from frozen tumor tissue from banked specimens of patients with pancreas, gastric, or colon cancer and from human cancer cell lines. Genotype and allelic frequencies were compared between the cancer cohort and two normal control databases using Fisher's exact test and odds ratio (OR). The Kaplan-Meier method was used to estimate the survival for patients with the CCK-B receptor SNP compared with those with the wild-type genotype. Immunohistochemical staining of cancer cells was done to detect the mutated receptor.Results:Colon and gastric cancer patients had similar genotype frequencies for the CCK receptor SNP as that reported in the normal population. In contrast, the prevalence of the SNP in subjects with pancreatic cancer was twice that of controls and other GI cancers. Survival was adversely affected by the presence of the SNP only in those with pancreatic cancer. Immunoreactivity for the mutated receptor was positive in pancreatic cancer tissues with the SNP but absent in other GI cancers.Conclusions:A SNP of the CCK receptor is significantly increased in patients with pancreatic cancer but not in those with other GI malignancies. Therefore, this SNP may be a potential biomarker for pancreatic cancer.",
author = "Jelal Alsubai and Gail Matters and Mcgovern, {Christopher O.} and Liao, {Jiangang (Jason)} and Gilius, {Evan L.} and Smith, {Jill P.}",
year = "2016",
month = "1",
day = "7",
doi = "10.1038/ctg.2015.61",
language = "English (US)",
volume = "7",
journal = "Clinical and Translational Gastroenterology",
issn = "2155-384X",
publisher = "Nature Publishing Group",

}

Germline mutation of the CCK receptor : A novel biomarker for pancreas cancer. / Alsubai, Jelal; Matters, Gail; Mcgovern, Christopher O.; Liao, Jiangang (Jason); Gilius, Evan L.; Smith, Jill P.

In: Clinical and Translational Gastroenterology, Vol. 7, e134, 07.01.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Germline mutation of the CCK receptor

T2 - A novel biomarker for pancreas cancer

AU - Alsubai, Jelal

AU - Matters, Gail

AU - Mcgovern, Christopher O.

AU - Liao, Jiangang (Jason)

AU - Gilius, Evan L.

AU - Smith, Jill P.

PY - 2016/1/7

Y1 - 2016/1/7

N2 - Objectives:Today, genetic biomarkers have been demonstrated to play an important role in identifying at-risk subjects for familial or inherited cancers. We have identified a single-nucleotide polymorphism (SNP) that results in missplicing of the cholecystokinin (CCK) receptor gene and expressing a larger mutated receptor in pancreatic cancer. The purpose of this study was to evaluate the significance and specificity of this SNP as a potential biomarker in patients with pancreatic cancer compared with other gastrointestinal (GI) cancers that also have CCK receptors.Methods:DNA was isolated and genotyped for the CCK receptor SNP from frozen tumor tissue from banked specimens of patients with pancreas, gastric, or colon cancer and from human cancer cell lines. Genotype and allelic frequencies were compared between the cancer cohort and two normal control databases using Fisher's exact test and odds ratio (OR). The Kaplan-Meier method was used to estimate the survival for patients with the CCK-B receptor SNP compared with those with the wild-type genotype. Immunohistochemical staining of cancer cells was done to detect the mutated receptor.Results:Colon and gastric cancer patients had similar genotype frequencies for the CCK receptor SNP as that reported in the normal population. In contrast, the prevalence of the SNP in subjects with pancreatic cancer was twice that of controls and other GI cancers. Survival was adversely affected by the presence of the SNP only in those with pancreatic cancer. Immunoreactivity for the mutated receptor was positive in pancreatic cancer tissues with the SNP but absent in other GI cancers.Conclusions:A SNP of the CCK receptor is significantly increased in patients with pancreatic cancer but not in those with other GI malignancies. Therefore, this SNP may be a potential biomarker for pancreatic cancer.

AB - Objectives:Today, genetic biomarkers have been demonstrated to play an important role in identifying at-risk subjects for familial or inherited cancers. We have identified a single-nucleotide polymorphism (SNP) that results in missplicing of the cholecystokinin (CCK) receptor gene and expressing a larger mutated receptor in pancreatic cancer. The purpose of this study was to evaluate the significance and specificity of this SNP as a potential biomarker in patients with pancreatic cancer compared with other gastrointestinal (GI) cancers that also have CCK receptors.Methods:DNA was isolated and genotyped for the CCK receptor SNP from frozen tumor tissue from banked specimens of patients with pancreas, gastric, or colon cancer and from human cancer cell lines. Genotype and allelic frequencies were compared between the cancer cohort and two normal control databases using Fisher's exact test and odds ratio (OR). The Kaplan-Meier method was used to estimate the survival for patients with the CCK-B receptor SNP compared with those with the wild-type genotype. Immunohistochemical staining of cancer cells was done to detect the mutated receptor.Results:Colon and gastric cancer patients had similar genotype frequencies for the CCK receptor SNP as that reported in the normal population. In contrast, the prevalence of the SNP in subjects with pancreatic cancer was twice that of controls and other GI cancers. Survival was adversely affected by the presence of the SNP only in those with pancreatic cancer. Immunoreactivity for the mutated receptor was positive in pancreatic cancer tissues with the SNP but absent in other GI cancers.Conclusions:A SNP of the CCK receptor is significantly increased in patients with pancreatic cancer but not in those with other GI malignancies. Therefore, this SNP may be a potential biomarker for pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84954178577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954178577&partnerID=8YFLogxK

U2 - 10.1038/ctg.2015.61

DO - 10.1038/ctg.2015.61

M3 - Article

C2 - 26741064

AN - SCOPUS:84954178577

VL - 7

JO - Clinical and Translational Gastroenterology

JF - Clinical and Translational Gastroenterology

SN - 2155-384X

M1 - e134

ER -